| Literature DB >> 26778677 |
Núria Amigó1,2, Roger Mallol1,2, Mercedes Heras2,3, Sergio Martínez-Hervás2,4, Francisco Blanco Vaca2,5,6, Joan Carles Escolà-Gil2,5,6, Núria Plana2,3, Óscar Yanes1,2, Lluís Masana2,3, Xavier Correig1,2.
Abstract
Recent studies have shown that pharmacological increases in HDL cholesterol concentrations do not necessarily translate into clinical benefits for patients, raising concerns about its predictive value for cardiovascular events. Here we hypothesize that the size-modulated lipid distribution within HDL particles is compromised in metabolic disorders that have abnormal HDL particle sizes, such as type 2 diabetes mellitus (DM2). By using NMR spectroscopy combined with a biochemical volumetric model we determined the size and spatial lipid distribution of HDL subclasses in a cohort of 26 controls and 29 DM2 patients before and after two drug treatments, one with niacin plus laropiprant and another with fenofibrate as an add-on to simvastatin. We further characterized the HDL surface properties using atomic force microscopy and fluorescent probes to show an abnormal lipid distribution within smaller HDL particles, a subclass particularly enriched in the DM2 patients. The reduction in the size, force cholesterol esters and triglycerides to emerge from the HDL core to the surface, making the outer surface of HDL more hydrophobic. Interestingly, pharmacological interventions had no effect on this undesired configuration, which may explain the lack of clinical benefits in DM2 subjects.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26778677 PMCID: PMC4726105 DOI: 10.1038/srep19249
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
HDL biochemical composition (mg/dl) of CT population and DM2 patients.
| CT (26) | DM2 (29) | p | |
|---|---|---|---|
| TG | 11.1 [10.2, 12.9] | 13.1 [11.1, 16.9] | 0.012 |
| EC | 28.5 [21.3, 32.3] | 17.8 [14.6, 22.1] | <0.001 |
| FC | 10.0 [8.5, 12.2] | 8.2 [6.2, 9.5] | 0.003 |
| PL | 59.7 [49.1, 68.9] | 45.0 [41.6, 50.1] | 0.002 |
| Prot | 113.0 [97.8, 127.8] | 98.5 [87.0, 105.0] | 0.007 |
Data are expressed as median ± 25–75. TG: triglycerides, EC: esterified cholesterol, FC: free cholesterol, PL: phospholipids, Prot: protein.
Figure 1Differences between the mean HDL radius measured by NMR and estimated by the Shen model.
The figure illustrates the differences between the mean radius obtained from NMR data and the radius derived from the Shen model for the CT group (n = 26) and the DM2 patients (n = 29).
HDL size and HDL lipid distribution between CT population and DM2 patients.
| CT (n = 26) | DM2 (n = 29) | p | |
|---|---|---|---|
| Radius (nm) | 4.7 [4.6, 4.8] | 4.5 [4.4, 4.6] | 0.002 |
| % Core lipids in the surface | 12 [0, 20] | 20 [13, 27] | 0.016 |
| Relative Volume (%) | |||
| Surface volume | |||
| Core lipids | 3 [0, 6] | 6 [4, 7] | 0.011 |
| Prot | 53 [51, 56] | 54 [51, 56] | 0.679 |
| PL | 37 [34, 39] | 34 [31, 37] | 0.022 |
| FC | 7 [6, 8] | 6 [5, 7] | 0.010 |
| Internal core | |||
| TG | 30 [26, 37] | 43 [36, 48] | <0.0001 |
| EC | 70 [63, 74] | 57 [52, 64] | <0.0001 |
The table shows the mean HDL radius for the CT and the DM2 groups, the percentage (%) of the traditional core lipids (CL) located in the surface shell, and the percentage (%) of the surface volume occupied by the CL, the protein, the phospholipids and the free cholesterol; and the percentage (%) of the inner core volume occupied by the triglycerides and cholesterol. All the results are expressed as medians ± 25–75. Prot: protein, PL: phospholipids, FC: free cholesterol, TG: triglycerides, EC: esterified cholesterol.
Figure 2Balance between large, medium and small HDL subclasses of CT population and DM2 patients.
(a) The figure illustrates the average of the normalised NMR spectra and the means of the three Lorentzian functions for the CT group (n = 26) and the DM2 patients (n = 29). The area under each curve represents the relative concentration of a particular subclass. (b) % of integrated area. Data are expressed as medians ± 25–75.
Figure 3Structural model for different subclasses of HDL particles.
The figure shows the differences in the amounts of core lipids located in the 2 nm shell depending on the lipoprotein size.
Treatment effects on the HDL biochemical composition (mg/dl) of DM2 patients.
| DM2 | FF | p1 | Ni | p2 | p3 | |
|---|---|---|---|---|---|---|
| TG | 13.3 [11.4, 17.4] | 12.9 [10.0, 16.7] | 0.149 | 13.3 [11.4, 16.2] | 0.192 | 0.702 |
| EC | 17.5 [14.6, 22.1] | 15.5 [13.7, 22.0] | 0.903 | 18.7 [14.5, 25.3] | 0.159 | 0.050 |
| FC | 8.5 [7.2, 9.5] | 6.9 [5.6, 8.7] | 0.027 | 7.9 [6.0, 10.5] | 0.931 | 0.023 |
| PL | 48.1 [42.8, 51.9] | 41.2 [37.6, 53.6] | 0.079 | 40.4 [31.6, 56.0] | 0.375 | 0.513 |
| Prot | 99.0 [86.8, 112.0] | 103.0 [81.8, 114.5] | 0.867 | 101.0 [87.8, 126.0] | 0.651 | 0.366 |
Data are expressed as medians ± 25–75 of the 24 DM2 subjects who finished both interventions. Comparative between the basal state and the post fenofibrate state (p1) and the post niacin state (p2); comparative between treatments (p3). FF: fenofibrate, Ni: niacin, TG: triglycerides, EC: esterified cholesterol, FC: free cholesterol, PL: phospholipids, Prot: protein.
Treatment effects on the HDL size and HDL lipid distribution of DM2 patients.
| DM2 | FF | p1 | Ni | p2 | p3 | |
|---|---|---|---|---|---|---|
| Radius (nm) | 4.5 [4.4, 4.6] | 4.4 [4.4, 4.7] | 0.305 | 4.6 [4.3, 4.7] | 0.259 | 0.042 |
| % Core lipids in the surface | 20 [11, 28] | 22 [16, 28] | 0.578 | 15 [9, 25] | 0.532 | 0.484 |
| Relative (%) volume | ||||||
| Surface volume | ||||||
| Core lipids | 5 [4, 7] | 5 [4, 7] | 0.958 | 4 [2, 8] | 0.689 | 0.881 |
| Prot | 53 [50, 56] | 55 [53, 59] | 0.205 | 56 [53, 58] | 0.170 | 0.958 |
| PL | 35 [33, 37] | 33 [29, 37] | 0.305 | 31 [29, 38] | 0.170 | 0.434 |
| FC | 6 [5, 7] | 5 [4, 6] | 0.140 | 6 [6, 7] | 0.434 | 0.159 |
| Internal core | ||||||
| TG | 43 [37, 49] | 40 [32, 48] | 0.434 | 40 [31, 48] | 0.205 | 0.217 |
| EC | 57 [51, 63] | 60 [52, 68] | 0.434 | 60 [52, 69] | 0.205 | 0.217 |
The table shows the treatment effects on the mean HDL radius, the percentage (%) of the traditional core lipids (CL) located in the surface shell, and the percentage (%) of the surface volume occupied by the CL, the protein, the phospholipids and the free cholesterol; and the percentage (%) of the inner core volume occupied by the triglycerides and cholesterol. All the results are expressed as medians ± 25–75 of the 24 DM2 subjects who finished both interventions. Comparative between the basal state and the post fenofibrate state (p1) and the post niacin state (p2); comparative between treatments (p3). FF: fenofibrate, Ni: niacin, Prot: protein, PL: phospholipids, FC: free cholesterol, TG: triglycerides, EC: esterified cholesterol.
Figure 4Treatment effects on the balance between large, medium and small HDL subclasses of DM2 patients (% integrated area).
Data are expressed as medians ± 25–75 of the 24 DM2 subjects who finished both interventions. FF: fenofibrate, Ni: niacin.